TY - JOUR
T1 - Role of hypertension on new onset congestive heart failure in patients receiving trastuzumab therapy for breast cancer
AU - Russo, Giulia
AU - Cioffi, Giovanni
AU - Gori, Stefania
AU - Tuccia, Fausto
AU - Boccardi, Lidia
AU - Khoury, Georgette
AU - Lestuzzi, Chiara
AU - Maurea, Nicola
AU - Oliva, Stefano
AU - Faggiano, Pompilio
AU - Tarantini, Luigi
PY - 2014/2
Y1 - 2014/2
N2 - BACKGROUND: Adjuvant trastuzumab therapy improves survival of Human Epidermal growth factor receptor 2 (HER2)-positive women with early breast cancer (EBC). Trastuzumab-induced cardiotoxicity is not uncommon. In the setting of community patients, the incidence, timing and phenotype of new onset congestive heart failure (CHF) is unknown. METHODS: Forty hundred and ninety nine consecutive HER2-positive women (mean age 55±11) with EBC treated with trastuzumab between January 2008 and June 2009 at 10 Italian institutions were followed-up for 1 year. We evaluated incidence, time of occurrence, clinical features associated with CHF. Left ventricular ejection fraction (LVEF) was evaluated by echocardiography at baseline and 3, 6, 9and 12 months during trastuzumab therapy. RESULTS: CHF occurred in 16 patients (3.2%), who were older, more hypertensive and with a higher degree of hypertension in comparison with patients who did not have CHF. All CHF patients had a significant reduction in LVEF with a mean peak of-12 points % detected at 3-month follow-up. CHF occurred in seven patients (44%) within 3-month follow-up, in four patients (25%) between 3-6 months, in three patients (19%) between 6-9 months and in two patients (12%) between 9 and 12 months. Trastuzumab was discontinued in 10 of 16 patients and re-started in five after LVEF recovery and clinical improvement. New onset CHF was predicted by the presence of hypertension [OR 2.9 (CI 1.1-7.9]). CONCLUSION: New onset CHF occurs seldom in HER2-positive women with EBC, prevalently in the first 6 months of therapy. CHF is associated with a significant reduction in LVEF and is predicted by a history of hypertension.
AB - BACKGROUND: Adjuvant trastuzumab therapy improves survival of Human Epidermal growth factor receptor 2 (HER2)-positive women with early breast cancer (EBC). Trastuzumab-induced cardiotoxicity is not uncommon. In the setting of community patients, the incidence, timing and phenotype of new onset congestive heart failure (CHF) is unknown. METHODS: Forty hundred and ninety nine consecutive HER2-positive women (mean age 55±11) with EBC treated with trastuzumab between January 2008 and June 2009 at 10 Italian institutions were followed-up for 1 year. We evaluated incidence, time of occurrence, clinical features associated with CHF. Left ventricular ejection fraction (LVEF) was evaluated by echocardiography at baseline and 3, 6, 9and 12 months during trastuzumab therapy. RESULTS: CHF occurred in 16 patients (3.2%), who were older, more hypertensive and with a higher degree of hypertension in comparison with patients who did not have CHF. All CHF patients had a significant reduction in LVEF with a mean peak of-12 points % detected at 3-month follow-up. CHF occurred in seven patients (44%) within 3-month follow-up, in four patients (25%) between 3-6 months, in three patients (19%) between 6-9 months and in two patients (12%) between 9 and 12 months. Trastuzumab was discontinued in 10 of 16 patients and re-started in five after LVEF recovery and clinical improvement. New onset CHF was predicted by the presence of hypertension [OR 2.9 (CI 1.1-7.9]). CONCLUSION: New onset CHF occurs seldom in HER2-positive women with EBC, prevalently in the first 6 months of therapy. CHF is associated with a significant reduction in LVEF and is predicted by a history of hypertension.
KW - breast cancer
KW - congestive heart failure
KW - hypertension
KW - trastuzumab
KW - women
UR - http://www.scopus.com/inward/record.url?scp=84896730242&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84896730242&partnerID=8YFLogxK
U2 - 10.2459/JCM.0b013e328365afb5
DO - 10.2459/JCM.0b013e328365afb5
M3 - Article
C2 - 24534802
AN - SCOPUS:84896730242
VL - 15
SP - 141
EP - 146
JO - Journal of Cardiovascular Medicine
JF - Journal of Cardiovascular Medicine
SN - 1558-2027
IS - 2
ER -